Department of Biomathematics, University of Thessaly School of Medicine, Larissa, Greece.
Biomarkers. 2013 Aug;18(5):425-35. doi: 10.3109/1354750X.2013.808263. Epub 2013 Jun 27.
Data from 30 pharmacogenomic studies that investigated MDR1 mRNA expression or gene variants (C3435T, G2677TA, C1236T) and response to therapy in acute myeloid leukaemia (AML) were synthesized. Anthracycline-based regimens were mainly used. MDR1 mRNA overexpression was associated with poor response to therapy [odds ratio (OR) = 2.49 95% confidence interval (CI) 1.38-4.50]. The gene variants were not associated with response to treatment; the generalized ORs, a genetic model-free approach, for the variants C3435T, G2677TA and C1236T were ORG = 0.86 (95% CI 0.55-1.37), ORG = 0.97 (95% CI 0.58-1.64) and ORG = 1.17 (95% CI 0.75--1.83), respectively. There is indication that MDR1 mRNA expression may be considered as a potential marker for response to chemotherapy in AML patients.
综合了 30 项研究药物代谢相关蛋白 1（MDR1）mRNA 表达或基因变异（C3435T、G2677TA、C1236T）与急性髓细胞白血病（AML）患者对治疗的反应的药代基因组学研究的数据。这些研究主要使用了蒽环类药物为基础的治疗方案。MDR1 mRNA 过表达与治疗反应不佳相关（比值比 [OR] = 2.49，95%置信区间 [CI] 1.38-4.50）。基因变异与治疗反应无关；C3435T、G2677TA 和 C1236T 三个基因变异的广义 OR（一种无遗传模型的方法）分别为 ORG = 0.86（95% CI 0.55-1.37）、ORG = 0.97（95% CI 0.58-1.64）和 ORG = 1.17（95% CI 0.75-1.83）。有迹象表明，MDR1 mRNA 表达可以被视为 AML 患者化疗反应的一个潜在标志物。
